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Abstract 
Background: Evidence has shown that the prevalence of depression is much higher among patients with tuberculo-
sis (TB) and this, in turn, may adversely impact compliance with anti-TB medications. Therefore, this systematic review 
and meta-analysis aimed to quantitatively summarize epidemiologic evidence on the prevalence of depression 
among patients with TB and formulate a recommendation for future clinical practice as well as research.
Methods: We followed the preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines 
to conduct this review. We searched PubMed, EMBASE, SCOPUS and Psych INFO to identify relevant studies that inves-
tigated the prevalence of depression among TB patients. We also supplemented our electronic search with manual 
searching to include all pertinent studies in the analysis. We used a Comprehensive Meta-Analysis software version 
3.0 (CMA 3.0) to conduct a meta-analysis. We conducted a subgroup and sensitivity analysis and Cochran’s Q- and 
the I2-statistics were used to assess heterogeneity. The evidence for the presence of publication bias was checked by 
using Egger’s test and visual inspection of the symmetry in funnel plots.
Results: We identified a total of 25 studies that included 4903 participants across seven countries. In our analysis, 
the pooled estimated prevalence of depression among TB patients was found to be 45.19% (95% CI 38.04–52.55). 
The prevalence was higher in MDR-TB 52.34% (95% CI 38.09–66.22) than non-MDR-TB 43.47% (95% CI 35.88–51.37) 
patients. We also found that the pooled prevalence of depression was higher among females 51.54% (95% CI 40.34–
62.60) when compared to males 45.25% (95% CI 35.19–55.71). The pooled prevalence of depression was 45.45% as 
measured by HRDS, and it was 55.62%, 45.52%, and 38.36% as measured by BDI, HADS and PHQ-9, respectively.
Conclusion: Our finding suggested that the pooled estimated prevalence of depression among tuberculosis 
patients was relatively high. Screening and management of depression among TB patients were warranted to allevi-
ate suffering. Moreover, the integration of tuberculosis program with regular psychiatry services may substantially 
reduce the burden.
Keywords: Prevalence, Depression, TB, Systematic review, Meta-analysis
© The Author(s) 2020. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, 
adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and 
the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material 
in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material 
is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the 
permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creat iveco 
mmons .org/licen ses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creat iveco mmons .org/publi cdoma in/
zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Background
Tuberculosis (TB) a chronic infectious disease, which 
is caused by Mycobacterium tuberculosis (MTB) bac-
teria, affects the lungs and other parts of the body [1]. 
The World Health Organization (WHO) report of 2019 
showed that approximately 10 million people fell ill with 
TB, 1.5 million people died of TB and 484,000 people fell 
ill with drug-resistant TB in 2018 [2]. On the other hand, 
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58 million people lives saved between 2000 and 2018 by 
efforts to end tuberculosis globally [2]. However, the high 
burden of TB on morbidity and mortality constitutes a 
significant concern in low and middle-income countries 
[2, 3]. Numerous risk factors have been associated with 
mortality that resulted from poor anti-TB medication 
adherence. Poor compliance with medications may lead 
to treatment default and result in severe medical compli-
cations, for example, multidrug-resistant TB (MDR-TB) 
[4].
Depression is among common mental health problems 
that occur in patients with tuberculosis, characterized by 
persistent depressed mood, lack of pleasure in everyday 
activities, reduced energy, vegetative symptoms, suicidal 
ideation and attempt and causing varying levels of social 
and occupational dysfunctions [5]. Depression is a major 
contributor to the overall global burden of disease and 
affected more than 264 million people of all ages in 2019 
[6]. Findings from different studies showed that approxi-
mately 800,000 people die due to suicide every year and 
over 50% of all people who die by suicide suffer from 
major depression [7, 8]. Evidence from the epidemiologi-
cal study also showed that the lifetime risk of suffering 
from depression among the general population is 7.2% 
and 4.4% in females and males, respectively [9].
Depression and tuberculosis are often coexisting in 
individuals. They share common risk factors, which sug-
gest the high magnitude of their comorbidity as reported 
by different studies to range from 10 to 52% [10, 11]. For 
example, the increase of pro-inflammatory cytokines 
characteristic of depression leads to reduced activation 
of the cellular and humoral immune systems and this, 
in turn, contributes to the progression of tuberculosis 
[11]. Similarly, infection resulted from tuberculosis can 
cause chronic inflammation, releasing pro-inflammatory 
cytokines that stimulate enzymes functioning at the cen-
tral nervous system and also some of the anti-TB medi-
cations may play a role in mental health problems such 
as depression [12]. When depression is comorbid with 
tuberculosis, it will lead to poor quality of life, lack of 
adherence to anti-Tb medications, progressions to MDR-
TB and finally end up with mortality resulting from the 
disease [13, 14].
Epidemiological findings from different studies showed 
different rates of prevalence of depression among patients 
with tuberculosis [15–19]. For example, a cross-sectional 
study that assessed the prevalence of depression among 
tuberculosis patients in Pakistan reported 47.2% [15]. In 
contrast, another cross-sectional study from Greece that 
assessed the prevalence of depression in patients with 
bronchial asthma, chronic obstructive pulmonary dis-
ease, and tuberculosis in a general hospital of chest dis-
eases reported 9.93% [16]. The disparities in the rates of 
prevalence may be attributed to variations in the assess-
ment tools of depression among TB patients.
A systematic review and meta-analysis was conducted 
in 2018 to quantify mental health problems such as 
depression, anxiety, and psychosis as well as the health-
related quality of life in patients with multidrug-resist-
ant tuberculosis (MDR-TB) [20]. This review included 
a total of 32 studies that assessed mental health prob-
lems including substance use disorders among MDR-TB 
patients across 20 countries and estimated the prevalence 
of mental health problems at baseline and after MDR-TB 
treatment initiation. This study reported that the pooled 
estimated prevalence of depression, anxiety, and psy-
chosis among MDR-TB patients was 50%, 16%, and 4%, 
respectively, before initiation of the tuberculosis medica-
tions. However, our review focuses on the prevalence of 
depression among tuberculosis patients irrespective of 
the severity of tuberculosis (MDR-TB or non-MDR-TB). 
Therefore, this study aimed to quantitatively summarize 
the prevalence of depression among TB patients and for-




We performed an extensive search of literature as sug-
gested in the guideline of reporting systematic review and 
meta-analysis (PRISMA) [21]. We have reviewed both 
published and gray literature on the prevalence of depres-
sion among patients with tuberculosis using the follow-
ing major databases: PubMed, SCOPUS, EMBASE, and 
Psych INFO. All published and unpublished articles up to 
December 2019 were included in the systematic review 
and meta-analysis. We conducted our search in PubMed 
using the following terms: “depression OR depressive 
disorder OR major depression OR depressive symptoms 
OR mental health problems OR distress OR psychologi-
cal distress AND tuberculosis OR TB OR MDR-TB OR 
respiratory disease AND prevalence OR magnitude OR 
epidemiology OR incidence”. We used specific-subjects 
headings for EMBASE and SCOPUS database searching. 
Besides, we have manually searched the reference lists of 
eligible articles.
Eligibility criteria
Evaluation of the relevant studies using their title and 
abstract was done before the retrieval of full-text arti-
cles for further screening, the two reviewers (BD and 
GA). A predefined inclusion and exclusion criteria were 
employed to screen the retrieved full articles and any dis-
agreement during the process was solved via discussion 
with a third reviewer (AB). Cross-sectional and other 
observational studies that assessed the prevalence of 
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depression among patients with tuberculosis (MDR-TB 
and non-MDR-TB patients) and published in the English 
language were included in the review. Duplicate stud-
ies, commentaries, reviews, letters, editorials, and short 
communications were excluded from the review.
Methods for data extraction and quality assessment
A predesigned standardized data extraction form was 
utilized to extract data from the studies included in the 
systematic review and meta-analysis. We have extracted 
the following information from each study: the name 
of the first author, publication year, study setting, study 
design, sample size, the prevalence of depression and 
data measurement tools used for assessing depression. 
Two reviewers extracted the data from the included stud-
ies independently and any disagreements raised during 
data extraction were resolved through discussion with 
a third reviewer. A modified version of the Newcastle–
Ottawa Scale (NOS) [22] was used to evaluate the quality 
of the included studies. An ascertainment of depressive 
symptoms, statistical quality, sample representativeness, 
sample size and comparability between participants were 
the domains NOS scale to assess the quality of individual 
studies.
Data synthesis and analysis
We used a comprehensive meta-analysis software ver-
sion 3.0 (CMA 3.0) to conduct this meta-analysis. The 
random effect meta-analysis model was used to esti-
mate the overall pooled estimated prevalence of depres-
sion  among patients with tuberculosis. The Q- and 
I2-statistics were used to check the heterogeneity among 
the studies included in the review [23]. The magnitude 
of statistical heterogeneity between studies was assessed 
using I2-statistic and values of 25, 50 and 75% were con-
sidered to represent low, medium and high, respectively 
[24, 25]. We have used subgroup and sensitivity analysis 
to explore the potential source of heterogeneity. The data 
assessment instrument that was used to assess depres-
sion, types of tuberculosis (MDR-TB and non-MDR-
TB), the gender of the study participants and the quality 
of studies were used to determine the possible source of 
heterogeneity between the studies. The funnel plot and 




Our electronic search engine and strategies resulted in a 
total of 739 articles. Additionally, we identified 9 articles 
by our manual search making the total articles of 748. Of 
these, 595 were excluded during the evaluation of dupli-
cate and titles as they did not meet the inclusion criteria. 
Our appraisal of abstract resulted in the exclusion of a 
further 117 articles. Therefore, a full-text of 36 studies 
were retrieved for further evaluation and 11 of these were 
excluded (Fig. 1).
Characteristics of included studies
In this review, a total of 25 studies were included in the 
final meta-analysis conducted in seven countries rep-
resenting 4903 participants. The characteristics of the 
study populations included in this study are depicted in 
Table 1. Out of 25 studies included in the review, seven 
were from Pakistan [15, 26–31], seven from India [32–
38], three from Nigeria [18, 39, 40], four from Ethiopia 
[11, 19, 41, 42], one from Brazil [43], one from China 
[44], one from Cameron [45], and one from Turkey 
[47]. The studies included in this review were published 
between 2006 and 2019, with the sample size ranging 
between 45 participants in India and 1252 participants 
in China. Depression among TB patients was predomi-
nantly measured using the PHQ-9 scale. The PHQ-9 was 
used in 12 studies, HADS in 7 studies, BDI in 3 studies, 
and the HDRS in 3 studies.
Quality of included studies
The Newcastle–Ottawa scale (NOS) scale with slight 
modifications was used to evaluate the quality of stud-
ies included in the review. Of the included studies, nine 
studies were high quality (NOS score 8 and above), nine 
moderate quality (NOS score between 6 and 7 inclusive) 
and seven were low-quality studies (NOS score less than 
or equal to 5) (Table 1).
Meta‑analysis
The prevalence of depression among patients 
with tuberculosis
Twenty-five studies that reported the prevalence of 
depression among patients with tuberculosis were 
included in the final analysis (Table  1). Based on the 
results of the random-effects meta-analysis model, 
the pooled estimated prevalence of depression among 
patients with tuberculosis was 45.19% (95% CI 38.04–
52.55). We found significant heterogeneity for this analy-
sis (I2 = 96.28%; p < 0.001) (see Fig. 2).
Subgroup analysis
The prevalence of depression in patients with MDR‑TB 
and non‑MDR‑TB
In this review, five of the studies reported the prevalence 
of depression in MDR-TB whereas 20 of them reported 
the prevalence of depression in non-MDR-TB cases. 
In the analysis of those studies which reported preva-
lence of depression among MDR-TB and non-MDR-TB 
cases, we found that the prevalence of depression was 
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Fig. 1 PRISMA flowchart of review search
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higher in MDR-TB 52.34% than non-MDR-TB 43.47%. 
A significant heterogeneity was found in both MDR-TB 
(I2 = 92. 55; p < 0.001) and non-MDR-TB (I2 = 99.26%; 
p < 0.001) (see Table 2).
Subgroup analysis of the prevalence of depression 
among TB patients by the assessment instrument
We also conducted a subgroup analysis by the type of 
assessment instruments used to measure depression. 
The pooled prevalence of depression was 45.45%, 55.62%, 
45.52% and 38.36% for studies that assessed depression 
using HRDS, BDI, HADS and PHQ-9, respectively. The 
heterogeneity was significant for all studies performed 
by BDI (I2 = 79.38%, p < 0.0001), HADS (I2 = 80.40%, 
p < 0.0001), HRDS (I2 = 87.87%, p < 0.0001) as well as 
PHQ-9 (I2 = 97.63%, p < 0.001) (see Table 2).
Table 1 Characteristics of studies included in the systematic review and meta-analysis














Aamir et al. [26] Pakistan 65 MDR-TB 2007–2008 HADS 36.9 Low
Anwar et al. 
[27]
Pakistan 60 TB 2009 BDI-II 86.1 70.8 80 Low
Javald et al. 
[28]
Pakistan 289 MDR-TB 2012–2013 HDRS 81.3 92.9 69.55 High
Ahmed et al. 
[29]
Pakistan 83 TB 2015 HDRS 49.4 Low
Hussain et al. 
[15]
Pakistan 108 TB 2007 HADS 50 45.3 46.3 Moderate
Amreen et al. 
[29]
Pakistan 100 TB 2014 PHQ9 56 Moderate
Mehreen et al. 
[30]
Pakistan 213 MDR-TB 2013 HDRS 65.5 High
Yilmaz et al. 
[46]
Turkey 208 TB 2014–2015 HADS 60.3 61.0 60.5 Moderate
Ravi et al. [32] India 120 TB 2017–2018 PHQ9 50 47.4 49 Moderate
Kumar et al. 
[33]
India 100 TB 2015 BDI-II 35 Low
Basu et al. [34] India 110 TB 2012 PHQ9 72 72.7 61.8 Moderate
Dahiya et al. 
[35]
India 106 TB 2016 BDI-II 42.86 77.3 50 Moderate
Arjun et al. [36] India 200 TB 2009–2011 HDRS 39.8 39.1 39.5 Moderate
Chandra et al. 
[37]
India 100 MDR-TB 2014–2015 HADS 56.3 52.8 55 Moderate
Mrinalini et al. 
[38]
India 100 TB/HIV 2012–2014 PHQ9 16 Moderate
Dos et al., 2016 
[43]
Brazil 86 MDR-TB 2013 HADS 28.3 46.2 31.4 Low
Wang et al. [44] China 1252 TB 2014–2015 PHQ9 18.4 16.76 17.7 High
Baba et al. [39] Nigeria 65 TB 2008 PHQ9 29.3 25 27.7 Low
Larson et al. 
[40]
Nigeria 371 TB/HIV 2013–2015 PHQ9 29.9 26.9 30 High
Ige et al. [18] Nigeria 88 TB 2010 HDRS 20 57.1 45.5 Low
Kehbila et al. 
[45]
Cameroon 265 TB 2015 PHQ9 22.6 38.2 61.1 High
Duko et al. [19] Ethiopia 417 TB 2014 HADS 43.8 43.2 43.4 High
Ambaw et al. 
[11]
Ethiopia 657 TB 2015 PHQ9 49.7 58.1 54 High
Dasa et al. [41] Ethiopia 403 TB 2017 PHQ9 51.9 High
Molla et al. [42] Ethiopia 415 TB 2018 PHQ9 39.6 51.9 31.1 High
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Subgroup analysis of the prevalence of depression 
among TB patients by gender of participants
In this review, 17 of the studies reported the prevalence 
of depression in male and female participants. Analysis 
of those studies which reported prevalence of depression 
in males and females, we found that the prevalence of 
depression was higher in females 51.54% (95% CI 40.34–
62.60) than males 45.25% (95% CI 35.19–55.71). A signifi-
cant heterogeneity was found in both females (I2 = 92. 55; 
p < 0.001) and males (I2 = 95.09; p < 0.001) (see Table 2).
Sensitivity analysis
To further investigate the potential source of hetero-
geneity in the analysis of the prevalence of depression 
among patients with TB, we conducted a sensitivity 
analysis by the type of depression, the assessment instru-
ment used to measure depression, and the quality of the 
included studies. When limiting the analysis to studies 
reported depression among MDR-TB, the prevalence of 
depression was found to be, 52.34%, as compared stud-
ies conducted on non-MDR-TB 43.47%, even though the 
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Fig. 2 Forest plot of the prevalence of depression among TB patients: a meta-analysis
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variation was not statistically significant (p = 0.320). In 
our sensitivity analysis based on the instrument used to 
measure depression among patients with TB, the highest 
prevalence of depression was found as it was measured by 
HDRS (45.45%) and the lowest prevalence was observed 
as measured by PHQ-9 (38.36%). The pooled estimated 
prevalence of depression was 55.62% as measured by BDI 
and 45.52% as measured by HADS. However, the differ-
ence observed in the prevalence of depression among TB 
patients based on the assessment instrument used was 
not statistically significant (p = 0.073) (see Table 2).
Finally, we also conducted the sensitivity analysis based 
on the quality of included studies, the prevalence depres-
sion was found relatively equal for high-quality (46.06%) 
and moderate-quality studies (47.85%) and slightly lower 
for poor-quality studies (40.54%, although the difference 
was not statistically significant (p = 0.657) (see Table 2).
Publication bias
The funnel plot was symmetric and Egger’s regression 
tests provided no evidence of substantial publication bias 
for the prevalence of depression among patients with 
tuberculosis (B = 2.70, SE = 2.59, p = 0.307) (see Fig. 3).
Discussion
This systematic review and meta-analysis of the preva-
lence of depression among patients with tuberculosis 
showed that the pooled estimated prevalence of depres-
sion was 45.55%. This figure was remarkably higher 
than the estimated prevalence of depression in the gen-
eral population which was 4.4% in 2017 [47]. Further, 
the pooled estimated prevalence of depression among 
patients with TB was much higher than the finding from 
a systematic review and meta-analysis conducted to 
assess the pooled estimated prevalence of depression and 
depressive symptoms among outpatients except TB that 
reported 27.0% [48]. Similarly, another systematic review 
and meta-analysis that assessed the prevalence of depres-
sion among patients with type 1 and 2 diabetes reported 
12% and 19.1%, respectively [49]. These variations might 
be because chronic diseases such as tuberculosis, which 
are highly susceptible to perceived stigma and poor social 
support, may precipitate the depressive feelings and, in 
fact, clinical depression increases as the severity of the 
illness increases. This is also supported by evidence that 
suggested individuals with chronic medical illnesses, 
such as tuberculosis, may show much higher rates of 
prevalence of depression when compared to other non-
chronic medical illnesses that range between 25 and 
33% [47, 50]. Further, evidence suggests that tuberculous 
infection may precipitate depression or depressive symp-
toms in individuals due to inflammatory response and 
dysregulation of the hypothalamic–pituitary–adrenal 
axis [51]. The dysregulation of the hypothalamic–pitui-
tary–adrenal axis has been suggested in the pathophysi-
ology of mood disorders including depression [52].
In our subgroup analysis, the pooled prevalence of 
depression among MDR-TB patients was found to be 
52.34% which was slightly higher than the prevalence of 
depression among non-MDR-TB patients (43.74), none-
theless, the variation between the observed prevalence 
among the two groups was not statistically significant. 
A recent systematic review and meta-analysis was con-
ducted in 2018 also showed that the estimated pooled 
prevalence of depression among patients with MDR-
TB was 50% before initiation of the medications [20]. 
Table 2 Sensitivity analysis of all studies based on type of TB, instrument used, and study quality of the included studies
MDR-TB multidrug-resistant tuberculosis, BDI Beck Depression Inventory, HADS The, Hospital Anxiety and Depression Scale, HDRS Hamilton Depression Rating Scale, 
PHQ-9 Patient Health Questionnaire-9




 MDR-TB 5 52.34 38.09–66.22 0.320
 Non-MDR TB 20 43.47 35.20–52.65
Instrument used
 BDI 3 55.62 32.00–76.94 0.073
 HADS 7 46.52 39.25–53.94
 HDRS 3 61.09 48.47–72.38
 PHQ-9 12 38.36 28.52–49.26
Quality of studies
 High 9 46.06 33.15–58.52 0.657
 Moderate 9 47.85 40.62–55.16
 Low 7 40.54 27.82–54.68
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Fig. 3 Funnel plot of standard error by logit event rate (publication bias)
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Further, this is also complemented by a finding from the 
Swedish Population-Based Cohort study that revealed the 
severity of depression increases as the severity of the ill-
ness increases [53]. These variations might be due to the 
severity of MDR-TB, the effect of using multiple drugs 
as well as lack of hope due to stressful life which might 
precipitate the progression of depression among patients 
with MDR-TB. Further, the higher rates of depression 
found among patients with MDR-TB may be explained 
by the negative psychological impact of being diagnosed 
and managed for MDR-TB.
We also conducted a subgroup and sensitivity analy-
sis on the prevalence of depression among TB patients 
based on the instruments used to measure depression, 
in this analysis the highest magnitude of depression was 
reported as it was measured by HDRS (61.09%) and the 
lowest prevalence was reported when it was measured 
by PHQ-9 (37.71%). The estimated prevalence of depres-
sion was 55.6% and 46.5% as it was measured by BDI 
and HADS, respectively. However, our test of signifi-
cance revealed that the observed difference in the mag-
nitude of depression across different rating instruments 
was not statistically significant (occurred by chance) 
(p = 0.07); suggesting the use of different instruments had 
no significant impact on the overall pooled prevalence of 
depression among TB patients. The highest prevalence of 
depression among TB patients was observed when stud-
ies using HDRS in comparison to other instruments. This 
might be due to most of the studies that used HDRS to 
assess depression were included only MDR-TB patients. 
The other possible reasons for the observed variation in 
the prevalence of depression across the various instru-
ments include the difference in the psychometric proper-
ties across the instruments as well as the use of different 
cut-off points (criteria) to define depression. For example, 
a study conducted to assess the psychometric compari-
son of PHQ-9 and HADS-D for measuring depression 
severity in primary care showed that both instruments 
differed significantly in categorizing the severity of 
depression [54]. Further, this is also supported by another 
study conducted to compare psychometric properties of 
the PHQ-9 and BDI-II for measuring of depression which 
reported that the BDI-II and PHQ-9 demonstrated ade-
quate reliability and validity in a similar way, but differed 
in labeling the severity of depression or depressive symp-
toms in patients with medical illnesses such as tubercu-
losis [55].
The prevalence of depression was higher in women 
(51.54%) when compared to men (42.25%). This is line 
with the result of a systematic review that assessed the 
gender disparity in the prevalence of depression among 
the patient population revealed being male sex was 63% 
less likely to develop depression when compared to being 
female sex [56]. The Global Burden of Disease (GBD) 
study also showed that the global annual prevalence of 
depression among women and men was 5.5% and 3.2%, 
respectively, in 2010, suggesting a 1.7-fold greater risk in 
women [57]. For instance, findings from epidemiological 
studies on adults also showed that women have higher 
rates of the depressive disorder compared to men, sug-
gesting on average, the ratio is 2:1; however, this ratio is 
not valid for all settings and substantially varies across 
different settings [58, 59]. A systematic review and meta-
analysis was conducted in 2017 synthesized data from 95 
studies representing 1,922,064 people in over 90 differ-
ent countries [60]. This review found a statistically sig-
nificant association for the gender difference in diagnoses 
of depression, with OR = 2.37 at the age of 12 years. This 
suggests that women are more likely to have depres-
sion and depressive symptoms when compared to men. 
Further, evidence from the epidemiological studies also 
suggested that the gender differences in socialization 
may play a significant role in the higher prevalence of 
depression as females socialized to be more nurturing 
and sensitive to the opinions of others when compared 
to males [61, 62]. Moreover, a meta-analysis performed 
to evaluate gender differences in adults also reported that 
females tend to use a more emotion-focused and think 
about their problems over in their minds and this, in 
turn, may increase the vulnerability of females in devel-
oping depression when compared to males [63]. Selec-
tive preventive interventions may be warranted to reduce 
depression in women [64, 65].
Strength and limitations
Strengths of the present study are the use of predefined 
search strategy, conducting data extraction and quality 
evaluation by two independent reviewers to minimize 
the possible reviewer bias. Performing sensitivity and 
subgroup analysis based on the severity of tuberculosis, 
an instrument used to assess depression, the gender of 
the study participants and the quality of the studies were 
among the strengths of the current study as well. The 
limitations of the study include a small number of stud-
ies that were used in our subgroup analysis which may 
reduce the precision of the estimate. Further, the majority 
of the studies were conducted in low- and middle-income 
countries. This may suggest tuberculosis is an underes-
timated problem in high-income Western countries and 
probably depression in TB patients is even more under-
estimated in Western countries.
Conclusion
In summary, the results of the current study indicated 
that the prevalence of depression among patients with 
tuberculosis was relatively higher. We also found a 
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higher rate of prevalence of depression among MDR-TB 
than non-MDR-TB patients. Further, women experi-
ence depression at higher rates when compared to men. 
However, the absolute reasons for the observed gender 
difference in the prevalence of depression need further 
investigations. The findings also suggest that attention 
needs to be given to the early screening and manage-
ment of depression to alleviate this suffering. Further, 
given the high prevalence of depression among patients 
with tuberculosis, counseling and routine social support 
should be an integral component of tuberculosis care 
and management programs. Moreover, the integration 
of tuberculosis program with regular psychiatry services 
may substantially reduce the burden of depression.
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